Pasten Consuelo, Lozano Mauricio, Rocco Jocelyn, Carrión Flavio, Alvarado Cristobal, Liberona Jéssica, Michea Luis, Irarrázabal Carlos E
Laboratorio de Fisiología Integrativa y Molecular, Programa de Fisiología, Centro de Investigación e Innovación Biomédica, Universidad de los Andes, Santiago 7620157, Chile.
Facultad de Medicina, Universidad de los Andes, Santiago 7620157, Chile.
Antioxidants (Basel). 2021 Oct 28;10(11):1724. doi: 10.3390/antiox10111724.
Oxidative stress produces macromolecules dysfunction and cellular damage. Renal ischemia-reperfusion injury (IRI) induces oxidative stress, inflammation, epithelium and endothelium damage, and cessation of renal function. The IRI is an inevitable process during kidney transplantation. Preliminary studies suggest that aminoguanidine (AG) is an antioxidant compound. In this study, we investigated the antioxidant effects of AG (50 mg/kg, intraperitoneal) and its association with molecular pathways activated by IRI (30 min/48 h) in the kidney. The antioxidant effect of AG was studied measuring GSSH/GSSG ratio, GST activity, lipoperoxidation, iNOS, and Hsp27 levels. In addition, we examined the effect of AG on elements associated with cell survival, inflammation, endothelium, and mesenchymal transition during IRI. AG prevented lipid peroxidation, increased GSH levels, and recovered the GST activity impaired by IRI. AG was associated with inhibition of iNOS, Hsp27, endothelial activation (VE-cadherin, PECAM), mesenchymal markers (vimentin, fascin, and HSP47), and inflammation (IL-1β, IL-6, Foxp3, and IL-10) upregulation. In addition, AG reduced kidney injury (NGAL, clusterin, Arg-2, and TFG-β1) and improved kidney function (glomerular filtration rate) during IRI. In conclusion, we found new evidence of the antioxidant properties of AG as a renoprotective compound during IRI. Therefore, AG is a promising compound to treat the deleterious effect of renal IRI.
氧化应激会导致大分子功能障碍和细胞损伤。肾缺血再灌注损伤(IRI)会引发氧化应激、炎症反应、上皮和内皮损伤以及肾功能停止。IRI是肾移植过程中不可避免的一个过程。初步研究表明,氨基胍(AG)是一种抗氧化化合物。在本研究中,我们探究了AG(50毫克/千克,腹腔注射)的抗氧化作用及其与肾脏中IRI(30分钟/48小时)激活的分子途径之间的关联。通过测量谷胱甘肽二硫化物/谷胱甘肽(GSSH/GSSG)比值、谷胱甘肽S-转移酶(GST)活性、脂质过氧化、诱导型一氧化氮合酶(iNOS)和热休克蛋白27(Hsp27)水平来研究AG的抗氧化作用。此外,我们还检测了AG对IRI期间与细胞存活、炎症、内皮和间充质转化相关的因素的影响。AG可防止脂质过氧化,提高谷胱甘肽(GSH)水平,并恢复被IRI损害的GST活性。AG与抑制iNOS、Hsp27、内皮激活(血管内皮钙黏蛋白、血小板内皮细胞黏附分子)、间充质标志物(波形蛋白、成束蛋白和热休克蛋白47)以及炎症(白细胞介素-1β、白细胞介素-6、叉头框蛋白3和白细胞介素-10)上调有关。此外,AG在IRI期间可减轻肾损伤(中性粒细胞明胶酶相关脂质运载蛋白、簇集素、精氨酸酶-2和转化生长因子-β1)并改善肾功能(肾小球滤过率)。总之,我们发现了AG作为IRI期间肾保护化合物的抗氧化特性的新证据。因此,AG是一种有前景的化合物,可用于治疗肾IRI的有害影响。